Emerging therapeutic targets in metastatic progression: A focus on breast cancer

Metastasis is the underlying cause of death for the majority of breast cancer patients. Despite significant advances in recent years in basic research and clinical development, therapies that specifically target metastatic breast cancer remain inadequate, and represents the single greatest obstacle...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmacology & therapeutics (Oxford) Ročník 161; s. 79 - 96
Hlavní autoři: Li, Zhuo, Kang, Yibin
Médium: Journal Article
Jazyk:angličtina
Vydáno: England 01.05.2016
Témata:
ISSN:0163-7258, 1879-016X, 1879-016X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Metastasis is the underlying cause of death for the majority of breast cancer patients. Despite significant advances in recent years in basic research and clinical development, therapies that specifically target metastatic breast cancer remain inadequate, and represents the single greatest obstacle to reducing mortality of late-stage breast cancer. Recent efforts have leveraged genomic analysis of breast cancer and molecular dissection of tumor-stromal cross-talk to uncover a number of promising candidates for targeted treatment of metastatic breast cancer. Rational combinations of therapeutic agents targeting tumor-intrinsic properties and microenvironmental components provide a promising strategy to develop precision treatments with higher specificity and less toxicity. In this review, we discuss the emerging therapeutic targets in breast cancer metastasis, from tumor-intrinsic pathways to those that involve the host tissue components, including the immune system.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0163-7258
1879-016X
1879-016X
DOI:10.1016/j.pharmthera.2016.03.003